Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...

Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents ...

It could be a real breakthrough for people at risk for HIV infection: A shot given every 6 months that reduces their risk by a whopping 96%.

In newly released data, lenacapavir, administered via a twice-yearly injection, has shown remarkable effectiveness at ...

Founded in 2008 with only three people in a small laboratory in Milton Park in Oxfordshire, England, Adaptimmune has since expanded into a globally recognized biotech company. Now, with hundreds of ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.